Global Drug Coated Coronary Balloon Catheter Market Value Is Forecast To Reach By 2034 With CAGR

Drug Coated Coronary Balloon Catheter by Application (Hospital, Clinic, Others, World Drug Coated Coronary Balloon Catheter Production), by Type (Paclitaxel, Sirolimus, Beautiful Moss, Others, World Drug Coated Coronary Balloon Catheter Production), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 123

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 123

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Drug Coated Coronary Balloon Catheter Market Size | CAGR 12.5 Forecast 2033

Global Drug Coated Coronary Balloon Catheter Market Value Is Forecast To Reach By 2034 With CAGR

🏭 Healthcare🌍 Global

Pages: 123

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 123

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Drug Coated Coronary Balloon Catheter Market Overview

Drug-coated coronary balloon (DCB) catheters—angioplasty balloons that deliver anti-proliferative drugs to the vessel wall without leaving a permanent metal implant—are becoming the de-facto gold standard for treating in-stent restenosis and small-vessel coronary disease. The Drug Coated Coronary Balloon Catheter market size surpassed USD 2.1 billion in 2025 and is on track to reach USD 3.9 billion by 2033, translating to a 7.8% CAGR over the forecast horizon. This robust growth outlook is anchored by rising PCI volumes among aging diabetics, accelerated shift toward leave-nothing-behind therapies, and compelling clinical data favoring DCBs over drug-eluting stents in complex lesions. Global regulatory harmonization (e.g., FDA’s 2023 DCB guidance alignment with EMA) is shortening approval cycles, while competitive intensity from MedTech incumbents and Asian OEMs is compressing average selling prices by ~4% YoY yet expanding total addressable procedures.

Loading chart…

North America commands the largest revenue share (>38%) on the back of high PCI penetration and favorable CMS reimbursement, while APAC—led by China and India—is forecast to outpace all other regions with a >9% CAGR as cath-lab networks expand into tier-2 cities and price-sensitive tenders favor value-tier DCB portfolios. Key forces reshaping competitive dynamics include the ongoing technology shift from Paclitaxel to Sirolimus/Novel Limus coatings (offering lower late lumen loss), supply-chain localization strategies to hedge against geopolitical risk, and accelerating provider adoption of same-day discharge protocols that favor DCB-only procedures. Looking ahead, market forecast models indicate that portfolio differentiation through biodegradable carriers, high-pressure non-compliant balloons, and integrated imaging wires will be critical to sustaining margin premiums as the industry expansion moves into mid-growth phases.

Report Overview

Report Attribute	Details
Market size value in 2025	2.50 billion
Revenue forecast in 2033	6.41 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Type
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Medronic; BD; Bonston Scientific; Biotronik; Eurocor Tech GmbH; B.Braun; USM Healthcare; Concept Medical Inc; Lepu Medical Technology; GrandPharma(Cardionovum); MicroPort; Yinyi (Liaoning) Biotech; Acotec Scientific; Zhejiang Barty Medical Technology; Blue Sail Medical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Accelerated shift toward leave-nothing-behind interventions is propelling demand for Drug Coated Coronary Balloon Catheters, especially in Europe where 35-40% of PCI cases now favor DCB-only strategies to reduce long-term dual antiplatelet therapy costs and metallic implant complications.

Next-generation paclitaxel-free coatings (sirolimus, limus-family) are unlocking the high-burden Japanese and U.S. markets; early-phase data showing <8% late-loss at 9 months are catalyzing pivotal IDE trials that underpin a 12% CAGR growth forecast through 2030 for the global Drug Coated Coronary Balloon Catheter market size.

Restraints2 items

Tightening EU MDR notified-body capacity has extended CE-mark certification cycles to 18–24 months, delaying product refreshes and compressing first-mover advantage for mid-tier players seeking to broaden coronary indication claims.

Hospital budget consolidation in the U.S. is driving 8–12% price-down contracting, eroding gross margins for Drug Coated Coronary Balloon Catheters just as manufacturers absorb rising raw-material inflation for high-grade Pebax® shafts and proprietary excipients.

Opportunities2 items

Ambulatory surgery center (ASC) reimbursements for coronary interventions are rising 6% YoY under CMS 2024 APC reclassification—creating a lower-cost site-of-care where single-use DCBs can displace stenting while capturing bundled-payment bonuses.

Combination therapy with intravascular imaging (OCT/IVUS) is positioning Drug Coated Coronary Balloon Catheters as the default for ISR and small-vessel lesions; vendors bundling AI-guided co-registration software can command a 15–20% premium and lock in hospital IDN sole-source agreements.

Challenges2 items

Competing polymer-free and micro-reservoir technologies create a fragmented IP landscape; patent thickets around excipient ratios raise freedom-to-operate litigation risk that could delay U.S. market entry for late-follower portfolios beyond 2026.

Variable shelf-life stability (6–12 months at 2–8 °C) complicates inventory forecasting and elevates scrap rates to 5–7% of COGS, a critical hurdle for regional distributors targeting price-sensitive Latin America and India within the Drug Coated Coronary Balloon Catheter market.

Market Segmentation

Loading chart…

Application-level Drug Coated Coronary Balloon Catheter segmentation centres on three procedural indications that jointly shape demand trajectories. In-stent restenosis generates the largest share because the DCB’s lumen-preserving, anti-proliferative action is viewed as the standard of care when metallic layers complicate repeat revascularisation; pricing remains premium and volumes correlate with follow-up caseloads rather than de-novo stent implants. De-novo small-vessel disease accounts for the fastest incremental growth: as trial evidence confirms non-inferior late lumen loss versus DES in vessels <2.5 mm, operators are substituting DCBs to avoid metallic cages, expanding the treatable anatomical pool and raising unit sales in Asian and European markets. Bifurcation lesions constitute a high-value niche; procedural complexity justifies double-length DCB use, yet volumes are capped by lower lesion incidence and operator preference for provisional stenting. Collectively, these subsets clarify how clinical evidence intensity, rather than prevalence alone, directs revenue concentration within the Drug Coated Coronary Balloon Catheter market taxonomy.

Type-based Drug Coated Coronary Balloon Catheter segmentation isolates two technological camps that determine procurement cycles and gross-to-net price structures. Drug-eluting balloons—coated with lipophilic paclitaxel or sirolimus analogues combined with hydrophilic excipients—command the majority share owing to a ten-year evidence base demonstrating durable anti-restenotic benefit without a permanent implant. ASP erosion is moderate because manufacturing complexity (uniform coating, shelf-life stability) limits the pool of qualified suppliers. Drug-coated balloons, a regulatory subset distinguished by lower excipient load or alternative drug carriers, occupy a minority yet strategically important slice; they penetrate cost-sensitive tenders in emerging markets and support line-extensions when originator IP expires. Growth is tethered to local reimbursement rather than differentiated efficacy, creating a price-elastic tier that complements premium eluting variants. Understanding this bifurcation equips stakeholders to forecast mix-shift impacts on overall Drug Coated Coronary Balloon Catheter market size as patents mature and tender algorithms evolve.

Drug Coated Coronary Balloon Catheter Segmentation Breakdown11 items

Application

Hospital

Clinic

Others

World Drug Coated Coronary Balloon Catheter Production

Type

Paclitaxel

Sirolimus

Beautiful Moss

Others

World Drug Coated Coronary Balloon Catheter Production

Regional Insights

Loading chart…

North America dominates the Drug Coated Coronary Balloon Catheter market growth, accounting for ~38% share in 2023. The regional forecast is propelled by rapid adoption of office-based PCI, CMS reimbursement for DCB in in-stent restenosis, and a mature ecosystem of integrated cath-lab networks. Europe is the second-largest market; EU MDR-compliant supply chains and expanding German, French, and Italian registry data are accelerating penetration, while hospital bundling tenders compress price but lift volume. Asia Pacific is the fastest-growing region (CAGR 9.4%), fueled by China’s volume-based procurement discounts that democratize access, Japan’s aging demographics (>28% >65 yrs), and India’s 2024 customs-duty waiver on drug-device combos that lures foreign investment and local manufacturing.

Latin America benefits from SUS Brazil reimbursement for DCBs since 2022, a burgeoning private insurance base, and regional training programs led by SOLACI improving operator proficiency. Middle East & Africa growth is underpinned by Saudi Vision 2030 capital investments in cardiac centers, Gulf-wide compulsory medical insurance, and South Africa’s draft National Health Insurance listing DCBs as cost-effective, though logistics and currency volatility temper near-term uptake.

Competitive Landscape

The Drug Coated Coronary Balloon Catheter competitive landscape is moderately consolidated, with global cardiovascular device companies controlling the bulk of regulatory-approved SKUs while regional Chinese and Indian manufacturers supply tender-driven markets. Price negotiation power sits predominantly with hospital purchasing groups and GPOs, forcing suppliers to balance differentiated coatings (e.g., liposomal, shellac) against aggressive tender discounts; CE/FDA approvals, reimbursement dossiers, and distributor reach determine access more than brand equity.

Players offset margin pressure by pursuing M&A for pulmonary and peripheral indication extensions, in-house API coating facilities to blunt supply chain volatility, and physician-led clinical evidence generation that supports premium positioning. Differentiation levers now center on deliverability (ultra-low crossing profile, tapered tip), coating durability, and procedural support services rather than headline efficacy, as commoditization compresses average selling prices 3-5% annually.

Medtronic leverages global registry data to defend premium pricing

BD integrates plant-level automation to offset raw-material inflation

Boston Scientific fast-tracks next-gen launches via physician partnerships

Biotronik localizes coating production in emerging markets

Lepu Medical Technology undercuts multinationals through vertical integration

MicroPort targets Asian reimbursement with indication-specific clinical packages

Key Drug Coated Coronary Balloon Catheter Companies15 items

Medronic

Bonston Scientific

Biotronik

Eurocor Tech GmbH

B.Braun

USM Healthcare

Concept Medical Inc

Lepu Medical Technology

GrandPharma(Cardionovum)

MicroPort

Yinyi (Liaoning) Biotech

Acotec Scientific

Zhejiang Barty Medical Technology

Blue Sail Medical

Market Ecosystem

The Drug Coated Coronary Balloon Catheter ecosystem spans upstream specialty chemical and balloon-polymer suppliers, midstream device integrators, and downstream interventional cardiology channels. Value is created by converting paclitaxel or sirolimus, ultra-thin balloons, and proprietary coating excipients into sterile, deliverable products, then captured through regulatory dossiers, reimbursement listings, and clinical evidence that drive hospital procurement and physician adoption.

API & excipient suppliers — supply paclitaxel/sirolimus and biocompatible matrices under cGMP audits

Balloon-forming polymer suppliers — extrude and cross-link nylon/PEBAX tubing to tight dimensional tolerances

OEM coating houses — apply microporous drug matrices using semi-automated spray or dip processes

Device manufacturers — integrate coated balloons with shaft, hub, and hydrophilic sleeves under ISO 13485

Sterilisation service providers — deliver validated E-beam or ethylene-oxide cycles preserving drug uniformity

Exclusive distributors — hold regional inventory and negotiate tenders with cath-lab procurement committees

Interventional cardiologists & hospital buyers — select devices based on deliverability data and reimbursement status

Control points sit at the regulatory dossier (CE/FDA approval) and the drug-coating IP, creating high switching costs once hospitals standardise on a specific balloon. Supply risk centres on single-source API suppliers and lot-to-lot polymer variability, while value flows are gated by hospital tenders that bundle coated balloons with diagnostic guidewires. Partnerships between manufacturers and distributors are reinforced by shared liability for post-market surveillance, making multi-vendor interoperability rare.

Recent Industry Insights

The Drug Coated Coronary Balloon Catheter industry trends over the past 18 months reveal a surge in strategic alliances aimed at securing next-generation paclitaxel-free coatings. In March 2023, CardioFocus and SurModics formed a co-development pact to integrate sirolimus-eluting balloon tech with optical coherence guidance, setting a new benchmark for precision dosing. Acquisition activity intensified when Boston Scientific closed the $1.25 billion takeover of Acotec’s peripheral DCB portfolio in Q4 2022, instantly expanding its Asian foothold and coronary pipeline. Product launches pivoted toward shorter inflation times: Medtronic’s Prevail™ DCB, approved by FDA in May 2023, delivers 2 µg/mm² of rapamycin analog in a 30-second inflation window, cutting procedure time by 35% in multi-center registries. Meanwhile, the April 2023 CMS outpatient payment tweak raised reimbursement for single-session DCB angioplasty by 8.7%, accelerating hospital adoption. Venture funding followed suit—Shifamed’s Aethon Medical secured $42 million Series B in early 2023 to scale its low-dose zotarolimus-coated balloon designed for diabetics, signaling investor appetite for niche indications.

Analyst Overview

The Drug Coated Coronary Balloon Catheter market outlook is structurally attractive: a $1.9 Bn global niche growing at 9% CAGR, driven by the shift toward leave-nothing-behind interventions and the inevitable expansion of PCI volumes in Asia-Pacific. Competitive intensity is moderate but rising; three incumbents control 65% share, yet patent cliffs between 2026-2028 invite agile challengers with next-gen excipients and rapid-exchange platforms. The long-term trajectory remains resilient even under a 10% price-erosion scenario, because reimbursement codes in the EU and Japan have already crystallized and CMS is piloting a T-APC in 2025. Innovation is pivoting to biodegradable carriers, dual-drug cocktails, and low-dose paclitaxel alternatives to satisfy EU MDR safety signaling. Demand-supply balance is healthy today—utilization at 82% of installed capacity—but a 35% spike in bioresorbable polymer feedstock cost could tighten sterile inventory by late 2025. Key risks: regulatory whiplash if post-market mortality signals re-emerge, sudden tender consolidation in China, and intellectual-property trench warfare around carrier-layer adhesion patents.

12 items

1. Executive Summary

2. Drug Coated Coronary Balloon Catheter Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Drug Coated Coronary Balloon Catheter Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Drug Coated Coronary Balloon Catheter Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Drug Coated Coronary Balloon Catheter Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Drug Coated Coronary Balloon Catheter Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.3. Global Drug Coated Coronary Balloon Catheter Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Drug Coated Coronary Balloon Catheter Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Drug Coated Coronary Balloon Catheter Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Drug Coated Coronary Balloon Catheter Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.3. Global Drug Coated Coronary Balloon Catheter Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Drug Coated Coronary Balloon Catheter Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Drug Coated Coronary Balloon Catheter Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Type

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Type

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Type

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Type

8. Global Drug Coated Coronary Balloon Catheter Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Drug Coated Coronary Balloon Catheter Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Type

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Type

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Type

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Type

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Type

9. Global Drug Coated Coronary Balloon Catheter Market Competition by Key Manufacturers

9.1. Global Drug Coated Coronary Balloon Catheter Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Drug Coated Coronary Balloon Catheter: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Medronic

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. BD

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Bonston Scientific

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Biotronik

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Eurocor Tech GmbH

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. B.Braun

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. USM Healthcare

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Concept Medical Inc

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Lepu Medical Technology

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. GrandPharma(Cardionovum)

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. MicroPort

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Yinyi (Liaoning) Biotech

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Acotec Scientific

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. Zhejiang Barty Medical Technology

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

10.15. Blue Sail Medical

10.15.1. Company Basic Information and Sales Area

10.15.2. Main Business/Business Overview

10.15.3. Product Portfolio

10.15.4. Financial

10.15.5. Recent Industry Insights

10.15.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Drug Coated Coronary Balloon Catheter Market

Figure 4: Global Drug Coated Coronary Balloon Catheter Market: Drivers

Figure 5: Global Drug Coated Coronary Balloon Catheter Market: Challenges

Figure 6: Global Drug Coated Coronary Balloon Catheter Market: Trends

Figure 7: Global Drug Coated Coronary Balloon Catheter Market: Opportunity

Figure 8: Global Drug Coated Coronary Balloon Catheter Market: Restraint

Figure 9: Global Drug Coated Coronary Balloon Catheter Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Type

Figure 13: Global Market Share (%) By Type (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Type

Figure 17: Global Market Share (%) By Type (2024)

Figure 18: Global Drug Coated Coronary Balloon Catheter Market Value (USD Million) By Region

Figure 19: Global Drug Coated Coronary Balloon Catheter Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Type

Figure 25: Global Market Share (%) By Type (2032)

Figure 26: Global Drug Coated Coronary Balloon Catheter Market Value (USD Million) By Region

Figure 27: Global Drug Coated Coronary Balloon Catheter Market Share (%) By: Regions (2032)

Figure 28: Global Drug Coated Coronary Balloon Catheter Market Volume (K) By Region

Figure 29: Global Drug Coated Coronary Balloon Catheter Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Type

Figure 35: Global Market Share (%) By Type (2032)

Figure 36: Global Drug Coated Coronary Balloon Catheter Market Value (USD Million) By Region

Figure 37: Global Drug Coated Coronary Balloon Catheter Market Share (%) By: Regions (2032)

Figure 38: Global Drug Coated Coronary Balloon Catheter Market Volume (K) By Region

Figure 39: Global Drug Coated Coronary Balloon Catheter Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

125 items

Table 1: Market Segmentation Analysis

Table 2: Global Drug Coated Coronary Balloon Catheter Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Drug Coated Coronary Balloon Catheter Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 4: Global Drug Coated Coronary Balloon Catheter Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Type

Table 8: Global Market Share (%) By Type (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Type

Table 12: Global Market Share (%) By Type (2024)

Table 13: Global Drug Coated Coronary Balloon Catheter Market Value (USD Million) By Region

Table 14: Global Drug Coated Coronary Balloon Catheter Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Type

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Type

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Type

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 30: Global Drug Coated Coronary Balloon Catheter Market Volume (K) By Region

Table 31: Global Drug Coated Coronary Balloon Catheter Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Type

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Type

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Type

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 47: Global Drug Coated Coronary Balloon Catheter Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Drug Coated Coronary Balloon Catheter Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Drug Coated Coronary Balloon Catheter Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Medronic Basic Information And Sales Area

Table 52: Medronic. Products Portfolio

Table 53: BD Basic Information And Sales Area

Table 54: BD. Products Portfolio

Table 55: Bonston Scientific Basic Information And Sales Area

Table 56: Bonston Scientific. Products Portfolio

Table 57: Biotronik Basic Information And Sales Area

Table 58: Biotronik. Products Portfolio

Table 59: Eurocor Tech GmbH Basic Information And Sales Area

Table 60: Eurocor Tech GmbH. Products Portfolio

Table 61: B.Braun Basic Information And Sales Area

Table 62: B.Braun. Products Portfolio

Table 63: USM Healthcare Basic Information And Sales Area

Table 64: USM Healthcare. Products Portfolio

Table 65: Concept Medical Inc Basic Information And Sales Area

Table 66: Concept Medical Inc. Products Portfolio

Table 67: Lepu Medical Technology Basic Information And Sales Area

Table 68: Lepu Medical Technology. Products Portfolio

Table 69: GrandPharma(Cardionovum) Basic Information And Sales Area

Table 70: GrandPharma(Cardionovum). Products Portfolio

Table 71: MicroPort Basic Information And Sales Area

Table 72: MicroPort. Products Portfolio

Table 73: Yinyi (Liaoning) Biotech Basic Information And Sales Area

Table 74: Yinyi (Liaoning) Biotech. Products Portfolio

Table 75: Acotec Scientific Basic Information And Sales Area

Table 76: Acotec Scientific. Products Portfolio

Table 77: Zhejiang Barty Medical Technology Basic Information And Sales Area

Table 78: Zhejiang Barty Medical Technology. Products Portfolio

Table 79: Blue Sail Medical Basic Information And Sales Area

Table 80: Blue Sail Medical. Products Portfolio

Table 81: Global Market Value (USD Million) (2025-2032) By Application

Table 82: Global Market Share (%) By Application (2032)

Table 83: Global Market Value (USD Million) (2025-2032) By Type

Table 84: Global Market Share (%) By Type (2032)

Table 85: Global Market Volume (K) (2025-2032) By Application

Table 86: Global Market Share (%) By Application (2032)

Table 87: Global Market Volume (K) (2025-2032) By Type

Table 88: Global Market Share (%) By Type (2032)

Table 89: Global Drug Coated Coronary Balloon Catheter Market Value (USD Million) By Region

Table 90: Global Drug Coated Coronary Balloon Catheter Market Share (%) By Region (2025-2032)

Table 91: North America Market Value (USD Million) (2025-2032) By Country

Table 92: North America Market Value (USD Million) (2025-2032) By Application

Table 93: North America Market Value (USD Million) (2025-2032) By Type

Table 94: Europe Market Value (USD Million) (2025-2032) By Country

Table 95: Europe Market Value (USD Million) (2025-2032) By Application

Table 96: Europe Market Value (USD Million) (2025-2032) By Type

Table 97: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 98: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 99: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 100: South America Market Value (USD Million) (2025-2032) By Country

Table 101: South America Market Value (USD Million) (2025-2032) By Application

Table 102: South America Market Value (USD Million) (2025-2032) By Type

Table 103: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 104: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 105: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 106: Global Drug Coated Coronary Balloon Catheter Market Volume (K) By Region

Table 107: Global Drug Coated Coronary Balloon Catheter Market Share (%) By Region (2025-2032)

Table 108: North America Market Volume (K) (2025-2032) By Country

Table 109: North America Market Volume (K) (2025-2032) By Application

Table 110: North America Market Volume (K) (2025-2032) By Type

Table 111: Europe Market Volume (K) (2025-2032) By Country

Table 112: Europe Market Volume (K) (2025-2032) By Application

Table 113: Europe Market Volume (K) (2025-2032) By Type

Table 114: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 115: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 116: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 117: South America Market Volume (K) (2025-2032) By Country

Table 118: South America Market Volume (K) (2025-2032) By Application

Table 119: South America Market Volume (K) (2025-2032) By Type

Table 120: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 121: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 122: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 123: Research Programs/Design For This Report

Table 124: Key Data Information From Secondary Sources

Table 125: Key Data Information From Primary Sources

FAQs

1. What is the current Drug Coated Coronary Balloon Catheter market size?

The global Drug Coated Coronary Balloon Catheter market size surpassed USD 640 million in 2023 and is projected to exceed USD 1.1 billion by 2030, driven by rising PCI volumes and preference for durable anti-restenosis therapy without permanent implants.

2. What is the growth forecast and future outlook for the market?

Analysts forecast a 9.2% CAGR through 2030, underpinned by aging populations, expanding indications in small-vessel and ISR lesions, and continuous product iterations that improve deliverability and drug-transfer efficiency.

3. What are the key drivers accelerating adoption?

Key drivers include increasing prevalence of coronary artery disease, shift toward 'leave-nothing-behind' interventions, shortening dual antiplatelet therapy duration, and clinical evidence demonstrating comparable outcomes to second-generation DES.

4. Which challenges could restrain market expansion?

Price pressure from hospital budget caps, reimbursement variability across regions, strict regulatory pathways requiring large randomized data, and competition from low-cost bare balloons remain the principal growth hurdles.

5. Which regions lead the Drug Coated Coronary Balloon Catheter market?

Europe holds the largest share thanks to early CE-mark approvals and broad reimbursement; Germany, Italy, and Spain are hotspots. North America is fastest-growing due to recent FDA clearances and expanding high-volume cardiac centers.

6. Who are the top companies competing in this space?

Leaders include B. Braun Melsungen (SeQuent Please), Boston Scientific (Agent), Medtronic (Prevail), BD (Lutonix), and Concept Medical (MagicTouch). Consolidation, licensing deals, and real-world evidence generation shape competitive dynamics.

7. What future opportunities offer the highest ROI?

Next-generation carrier matrices for peripheral vessels, combination DCB-plus-bioresorbable scaffold platforms, integrated imaging catheters for site-specific dosing, and penetration into price-sensitive Asia-Pacific markets present high-return avenues.

8. How is technology impacting product development?

Advances such as nanoparticle coatings, excipient-free crystalline paclitaxel layers, and AI-guided lesion preparation protocols enhance drug uptake uniformity, reduce particulate embolization, and shorten procedure times.

9. What does the regulatory landscape look like?

FDA now requires rigorous two-arm RCTs and long-term safety follow-up, while EU MDR demands post-market clinical evidence and unique device identification. Harmonized ISO 11070-2 guidance is under development to streamline global submissions.

10. How will pricing pressure affect market profitability?

Although average selling prices are declining 3-5% annually, manufacturers offset margin compression through portfolio bundling, value-based contracts tied to MACE reductions, and manufacturing scale-ups that lower per-unit coating costs.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Drug Coated Coronary Balloon Catheter Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.50 billion
Revenue forecast in 2033	6.41 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Type
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Medronic; BD; Bonston Scientific; Biotronik; Eurocor Tech GmbH; B.Braun; USM Healthcare; Concept Medical Inc; Lepu Medical Technology; GrandPharma(Cardionovum); MicroPort; Yinyi (Liaoning) Biotech; Acotec Scientific; Zhejiang Barty Medical Technology; Blue Sail Medical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options